Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke

NCT ID: NCT07044830

Last Updated: 2025-07-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

425 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-28

Study Completion Date

2031-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to evaluate whether early treatment of obstructive sleep apnea with continuous positive airway pressure in ischemic stroke patients has a favorable effect on functional recovery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Obstructive sleep apnea (OSA) is present in more than 70% of acute stroke patients, and has been related to poor short-and long-term outcomes. The treatment of choice for OSA is continuous positive airway pressure (CPAP).

The objective of this prospective, multicenter, randomized study is to evaluate the impact of CPAP treatment on clinical outcomes in post-stroke patients. Respiratory polygraphy will be performed in all eligible participants, and those with severe OSA will be randomized to receive either CPAP therapy or conservative management. CPAP use will initiated within the first 48-72 hours of hospital admission and continued through 2 years follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Severe OSA treated

AHI≥30: treated with CPAP

Group Type ACTIVE_COMPARATOR

CPAP

Intervention Type DEVICE

Automatically-adjusting continuous positive airway pressure (CPAP)

Severe OSA untreated

AHI≥30: without CPAP

Group Type NO_INTERVENTION

No interventions assigned to this group

No OSA

AHI\<5

Group Type NO_INTERVENTION

No interventions assigned to this group

Mild OSA

5≥AHI\<15

Group Type NO_INTERVENTION

No interventions assigned to this group

Moderate OSA

15≤AHI\<30

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPAP

Automatically-adjusting continuous positive airway pressure (CPAP)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Supratentorial non-lacunar ischemic stroke, including anterior, middle, and posterior cerebral artery territories
* Aged 18 to 80 years
* Symptom onset or symptom recognition to admission \< 12 hours
* NIHSS score ≥ 4 and ≤ 20 at enrollment
* Signed informed consent form obtained from the participant or their legal representative

Exclusion Criteria

* Prior stroke
* Previous diagnosis of OSA with current CPAP use or previously failed CPAP
* Pre-stroke disability (mRS \> 1)
* Coma or stupor
* Orotracheal intubation
* Clinical instability or severe pre-existing illness (e.g., heart failure, oxygen-dependent COPD, renal or hepatic failure)
* Psychomotor agitation
* High likelihood of neurosurgical intervention within the first 48 hours
* Oxygen therapy \>2 L/min
* Known severe neurological disease (e.g., dementia, Parkinson's disease, multiple sclerosis, or other neurodegenerative conditions)
* Chronic alcohol or drug use with high risk of withdrawal during hospitalization
* Pregnant or suspected pregnant women
* Inability to complete follow-up for any reason
* Any contraindication to CPAP use
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

Sponsor Role collaborator

ResMed Foundation

OTHER

Sponsor Role collaborator

Hospital das Clínicas de Ribeirão Preto

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Millene Rodrigues Camilo

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital das Clínicas, Ribeirão Preto Medical School, University of São Paulo

Ribeirão Preto, São Paulo, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Millene Camilo, MD, PhD

Role: CONTACT

+55-16-36059075

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Millene Camilo, MD, PhD

Role: primary

+55-16-36021000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20802619.2.0000.5440

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sleep Apnea Treatment After Stroke (SATS)
NCT00282815 TERMINATED PHASE2
Stroke and CPAP Outcome Study 3
NCT06029959 COMPLETED NA
Addressing Sleep Apnea Post-Stroke/TIA
NCT04322162 ACTIVE_NOT_RECRUITING NA